The Cavendish Impact Capital Life Science Fund will be formally announced at the 8th Cavendish Global Health Impact Forum taking place September 18 – 21, 2016 in Phoenix, AZ.Continue reading
Author Archive: AZBio
Mara G. Aspinall, Diagnostic Industry Leader, Named Arizona Bioscience Leader of the Year
The Arizona Bioindustry Association has named Mara G. Aspinall as the 2016 Jon W. McGarity Arizona Bioscience Leader of the Year in recognition of her leadership locally, nationally, and internationally in the field of biomedical diagnostics and for her roles as an active leader in Arizona’s life science community.Continue reading
Explore Thirty-Two Exciting Life Science Investment Opportunities at the White Hat Life Science Investor Conference in Phoenix this September.
A collaboration between the State Bio Associations of the Rocky Mountain Southwest, White Hat 2016 will connect investors with 32 exciting companies in the fields of Diagnostics, Therapeutics, Medical Devices, and Health IT.Continue reading
Capstone JV closes $1M+ Series B Round
Capstone Therapeutics Announces That Its Joint Venture, LipimetiX Development, Inc., Has Closed a Series B-1 Preferred Stock Offering
New Medical Device User Fee Agreement Sets the Stage For Continued Progress in FDA Performance
Latest Deal Builds on Success of MDUFA IIIContinue reading
Avery Therapeutics Awarded NIH SBIR
Avery Therapeutics, Inc., a pre-clinical stage company dedicated to advancing tissue-engineered therapeutics to treat diseases and injuries to human muscle, has been awarded a $483k SBIR grant from the National Institutes of Health to develop manufacturing, cryopreservation, storage and reconstitution methods for Avery’s first product MyCardia™. Continue reading
Marni Landry of the Paradise Valley High School CREST Program Named Arizona Bioscience Educator of the Year
The Arizona Bioindustry Association has named Marni Landry, BS, M.Ed of Paradise Valley High School as the 2016 Michael A. Cusanovich Bioscience Educator of the Year in recognition of her dedication in the classroom and her commitment to designing bioscience education programs and curriculum to help inspire and create tomorrow’s bioscience leaders.Continue reading
Insys Therapeutics Announces First Patient Enrolled in Phase II Trial for the Treatment of Cocaine Dependence Using Pharmaceutical Cannabidiol
Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) today announced enrollment of the first patient in a Phase II clinical trial for the treatment of cocaine dependence using its pharmaceutical cannabidiol (CBD) product candidate. The study is being conducted by Dr. Didier Jutras-Aswad, MD, at the University of Montreal Hospital Research Center (CRCHUM) and is supported by the Canadian Institutes of Health Research (CIHR) and the Company.Continue reading
FDA Allows NuvOx Pharma’s IND to Initiate Phase Ib Clinical Trial in Stroke.
Evan Unger, MD, President and CEO of NuvOx, announced that the FDA has allowed an investigational new drug application (IND) for NVX-208 (dodecafluoropentane emulsion) to be tested in a Phase Ib trial in stroke patients.
$7M NIH Asthma Grant to UA College of Medicine – Tucso
Led by Dr. Monica Kraft, researchers will use the National Institutes of Health grant to conduct a five-year study to investigate the interrelationship of genetic mediators to reduce lung inflammation and attacks in asthma patients.Continue reading